BLUEBIRD BIO Forum: Community User: maka

Seam, bist du noch dabei?

Oppenheimer analyst Mark Breidenbach upgrades bluebird bio (NASDAQ:BLUE) from Perform to Outperform and announces $135 price target.

bluebird bio (BLUE) Presents At 2019 ASH Annual Meeting - Slideshow https://seekingalpha.com/article/4311921?source=ansh $BLUE

https://finance.yahoo.com/news/bluebird-bio-presents-data-demonstrating-213000565.html?theme=2&_v=1&color=1&hl=en&sp=1

Schwer einzuordnen gerade. Gewinnmitnahmen vom WE? Angst vor schlechten Ergebnissen?

Heute Abend wird es sich entscheiden 🙄

Ehh falsche Richtung :-D

4 stehen jetzt noch aus 😉

Und die nächste positive News New data from an ongoing open-label Phase 1/2 clinical trial, HGB-206, evaluating bluebird bio's (NASDAQ:BLUE) LentiGlobin gene therapy in sickle cell disease (SCD) patients showed a significant treatment benefit. The results were presented at ASH in Orlando

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting and Exposition.

Ja, seit einer Woche

Bist du auch investiert, Billi?

Nur ne andere Quelle ;-)

Monday bluebird bio Inc (NASDAQ: BLUE): Phase 3 data for lentiglobin – HGB-212 in transfusion-dependent thalassemia and the β0/β0genotype and lentiglobin – HGB-207 in non-β0/β0 transfusion-dependent thalassemia

Fast alles jetzt übers Wochenende

LentiGlobin - HGB-210 Sickle Cell Disease (SCD) Phase 2 Phase 3 trial to be initiated by end of 2019. LentiGlobin - HGB-212 Northstar-3 TDT and the β0/β0genotype Phase 3 Phase 3 presentation of data at ASH December 9, 2019, 5:30 p.m ET. bb2121 - KarMMa Relapsed/refractory multiple myeloma Phase 2 Phase 2 data due by the end of 2019. LentiGlobin - HGB-207 Northstar-2 non-β0/β0 transfusion-dependent thalassemia (TDT) Phase 3 Phase 3 presentation of data at ASH December 9, 2019, 6pm. Lenti-D - Starbeam Childhood cerebral adrenoleukodystrophy (CCALD) Phase 2/3 Phase 2/3 updated data September 18, 2019 noted 88% (N=15/17) continue to be alive and MFD-free. LentiGlobin - HGB-204 β-Thalassemia Phase 1/2 Updated data due at EHA June 14, 2019 noted 3.8 years of transfusion independence in patients who do not have a β0/β0 genotype. LentiGlobin - HGB-206 Sickle disease Phase 1/2 Phase 1/2 presentation of data due at ASH December 7, 2019, 5:30pm. bb21217 Multiple Mye loma Phase 1 Phase 1 data due at ASH December 9, 2019, 6:45 p.m. ET.